EXCLUSIVE LICENSE AGREEMENT between Reata Pharmaceuticals, Inc. and KU Center for Technology Commercialization, Inc.License Agreement • November 20th, 2015 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Kansas
THIS LICENSE Agreement (“Agreement”) is entered into this 26th day of September, 2014 by and between the KU CENTER FOR TECHNOLOGY COMMERCIALIZATION, INC, a Kansas non-profit § 501(c)(3) corporation, having its principal place of business at 3901 Rainbow Boulevard, Kansas City, Kansas 66160, hereinafter referred to as “KUCTC” or “Licensor,” and “REATA PHARMACEUTICALS, INC.” having its principal place of business at 2801 Gateway Drive, Suite 150, Irving, Texas 75063, hereinafter referred to as “Licensee.”
ContractLicense Agreement • November 20th, 2015 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***]. AN UNREDACTED VERSION OF THIS EXHIBIT HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXCLUSIVE LICENSE and SUPPLY AGREEMENT by and between REATA PHARMACEUTICALS, INC. and KYOWA HAKKO KIRIN CO. LTD.Supply Agreement • November 20th, 2015 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Exclusive License and Supply Agreement (this “Agreement”) effective as of December 24, 2009 (the “Effective Date”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
COLLABORATION AGREEMENT between REATA PHARMACEUTICALS, INC. and ABBOTT PHARMACEUTICALS PR LTD. Dated as of December 9, 2011Collaboration Agreement • November 20th, 2015 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS COLLABORATION AGREEMENT (this “Agreement”) is entered into as of December 9, 2011 (the “Effective Date”) by and between REATA PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and ABBOTT PHARMACEUTICALS PR LTD., a Bermuda corporation having its principal place of business at 2 KM 58.2, Cruce Davila, Barceloneta 00617, Puerto Rico (“Abbott”). Reata and Abbott are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
